Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AEROJET ROCKETDYNE HOLDINGS, INC.AJRD · Entity 111042 | Director | February 15, 2019 | February 19, 2019 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director | March 01, 2024 | March 05, 2024 |
| LILIS ENERGY, INC.LLEX · Entity 147943 | Director | January 31, 2018 | February 02, 2018 |
| Research Solutions, Inc.RSSS · Entity 6984 | Director | November 12, 2025 | December 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AEROJET ROCKETDYNE HOLDINGS, INC.
Report date February 15, 2019 · Filed February 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Rabbi Trust | 63,695 |
Reported balance
After 2019-02-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-02-15 · Grant · Acquired 435 · Balance 63,695 F1: Effective March 24, 2010, the Board of Directors approved a Director Compensation Program which allows Directors to elect to receive Aerojet Rocketdyne Holdings, Inc. common stock in lieu of their cash compensation. The number of shares of common stock shown reflects the common stock this Reporting Person is entitled to receive in lieu of his annual cash retainer fee paid quarterly. F2: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. |
| Common StockSEC Table I · non-derivative | IndirectBy Rabbi Trust | 63,912 |
Reported balance
After 2019-02-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-02-15 · Grant · Acquired 217 · Balance 63,912 F2: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. F3: Pursuant to the Director Compensation Program, if a Director elects to receive common stock in lieu of at least 50% of his cash compensation, the Company will grant restricted shares equal in value to 50% of the amount of cash compensation he elects to receive in common stock. Such restricted shares will vest on the earlier of (i) the date of the Director's retirement from the Board, and (ii) one year after the grant date. The number of shares of common stock shown reflects the grant of restricted shares. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2019-02-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Effective March 24, 2010, the Board of Directors approved a Director Compensation Program which allows Directors to elect to receive Aerojet Rocketdyne Holdings, Inc. common stock in lieu of their cash compensation. The number of shares of common stock shown reflects the common stock this Reporting Person is entitled to receive in lieu of his annual cash retainer fee paid quarterly.
F2: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors.
F3: Pursuant to the Director Compensation Program, if a Director elects to receive common stock in lieu of at least 50% of his cash compensation, the Company will grant restricted shares equal in value to 50% of the amount of cash compensation he elects to receive in common stock. Such restricted shares will vest on the earlier of (i) the date of the Director's retirement from the Board, and (ii) one year after the grant date. The number of shares of common stock shown reflects the grant of restricted shares.
IOVANCE BIOTHERAPEUTICS, INC.
Report date March 01, 2024 · Filed March 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2024-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-01 · Grant · Acquired 50,000 · Balance 50,000 F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
F2: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
LILIS ENERGY, INC.
Report date January 31, 2018 · Filed February 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 466,922 |
Reported balance
After 2018-01-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-01-31 · Grant · Acquired 38,217 · Balance 466,922 F1: Represents restricted stock granted by the Issuer the Reporting Person on January 31, 2018 for Reporting Person's service on the Board of Directors. F2: Includes 10,000 vested Restricted Stock Units (RSU's), of which 3,334 RSU's vested on January 29, 2016, 3,333 RSU's vested on January 29, 2017 and 3,333 RSU's vested on January 29, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted by the Issuer the Reporting Person on January 31, 2018 for Reporting Person's service on the Board of Directors.
F2: Includes 10,000 vested Restricted Stock Units (RSU's), of which 3,334 RSU's vested on January 29, 2016, 3,333 RSU's vested on January 29, 2017 and 3,333 RSU's vested on January 29, 2018.
Research Solutions, Inc.
Report date November 12, 2025 · Filed December 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 484,608 |
Reported balance
After 2025-11-12 transaction · row 1
1 source rowRow 1 · 2025-11-12 · Exercise / conversion · Acquired 75,000 · Balance 484,608 |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2035-11-11 | Direct | 50,000 |
Reported balance
After 2025-11-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-12 · Grant · Acquired 50,000 · Balance 50,000 F1: 1/3rd of the options vest on November 12, 2026 and 1/12th of the options vest on the last day of each quarter beginning December 31, 2026 until fully vested. |
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2025-12-03 | Direct | 0 |
Reported balance
After 2025-11-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-12 · Exercise / conversion · Disposed 75,000 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: 1/3rd of the options vest on November 12, 2026 and 1/12th of the options vest on the last day of each quarter beginning December 31, 2026 until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2025 Filed Dec 12, 2025 21:32 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionOption to purchase common stock · Derivative | 75,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001104659-25-120763 · tm2531395-5_4seq1.xml · derivative · entry 3 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2025 Filed Dec 12, 2025 21:32 UTC | Research Solutions, Inc. RSSS · Entity 6984 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001104659-25-120763 · tm2531395-5_4seq1.xml · derivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-11-11 F1 · derivative.exercise_date: 1/3rd of the options vest on November 12, 2026 and 1/12th of the options vest on the last day of each quarter beginning December 31, 2026 until fully vested. Read SEC document |
| November 12, 2025 Filed Dec 12, 2025 21:32 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionCommon Stock | 75,000 | $0.70 | $52,500.00 |
DisclosureSEC source: 0001104659-25-120763 · tm2531395-5_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 484,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 18, 2025 18:51 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionOption to purchase common stock · Derivative | 75,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001104659-25-060722 · tm2518351-1_4seq1.xml · derivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 18, 2025 18:51 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionCommon Stock | 75,000 | $1.10 | $82,500.00 |
DisclosureSEC source: 0001104659-25-060722 · tm2518351-1_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2025 Filed Jun 4, 2025 17:34 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001104659-25-056481 · tm2517184-1_4seq1.xml · derivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2025 Filed Jun 4, 2025 17:34 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionCommon Stock | 50,000 | $1.05 | $52,500.00 |
DisclosureSEC source: 0001104659-25-056481 · tm2517184-1_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 18:26 UTC | Research Solutions, Inc. RSSS · Entity 6984 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001104659-24-117869 · tm2428421-4_4seq1.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-11-11 F1 · derivative.exercise_date: 1/3rd of the options vest on November 12, 2025 and 1/12th of the options vest on the last day of each quarter beginning December 31, 2025 until fully vested. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:53 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031110 · tm248017-6_4seq1.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 00:52 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 250,000 | $9.15 | $2,287,500.00 |
DisclosureSEC source: 0001104659-24-025684 · tm246751-1_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,150 F2 · shares: Such shares purchased pursuant to Issuer's underwritten offering, which priced on 02/20/2024. F4 · balance_after: Consists of 30,150 shares held in Keogh retirement account plus 40,000 shares as a result of exercised stock options plus 250,000 shares acquired in this offering. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 20:02 UTC | Research Solutions, Inc. RSSS · Entity 6984 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001104659-23-124795 · tm2332543-2_4seq1.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-12-05 F1 · derivative.exercise_date: 1/3rd of the options vest on December 6, 2024 and 1/12th of the options vest on the last day of each quarter beginning December 31, 2024 until fully vested Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 20:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 10,000 | $5.56 | $55,600.00 |
DisclosureSEC source: 0001104659-23-101954 · tm2326424-1_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 248,633 F1 · ownership.nature: These shares are held by a family trust for which the reporting person is a trustee. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:21 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 51,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-069508 · tm2318216-5_4seq1.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,955 Underlying: Common Stock · 51,955 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| January 16, 2023 Filed Jan 17, 2023 21:52 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001104659-23-004393 · tm233750d1_4.xml · derivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2023 Filed Jan 17, 2023 21:52 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionCommon Stock | 50,000 | $1.15 | $57,500.00 |
DisclosureSEC source: 0001104659-23-004393 · tm233750d1_4.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 10,000 | $6.15 | $61,500.00 |
DisclosureSEC source: 0001104659-22-129516 · tm2233363-1_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,150 Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 14:38 UTC | Research Solutions, Inc. RSSS · Entity 6984 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001104659-22-125783 · tm2232125-4_4seq1.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-12-07 Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:17 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 10,000 | $6.31 | $63,100.00 |
DisclosureSEC source: 0001104659-22-123244 · tm2231611-1_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 238,633 F1 · ownership.nature: These shares are held by a family trust for which the reporting person is a trustee. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 02:44 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 10,000 | $6.18 | $61,800.00 |
DisclosureSEC source: 0001104659-22-122555 · tm2231429-3_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 228,633 F1 · ownership.nature: These shares are held by a family trust for which the reporting person is a trustee. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 20:15 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001104659-22-094430 · tm2224516-1_4seq1.xml · derivative · entry 3 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options and hold of underlying shares. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 20:15 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 40,000 | $5.65 | $226,000.00 |
DisclosureSEC source: 0001104659-22-094430 · tm2224516-1_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options and hold of underlying shares. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 51,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071055 · tm2218366-6_4seq1.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,204 Underlying: Common Stock · 51,204 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 00:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 10,000 | $6.80 | $68,000.00 |
DisclosureSEC source: 0001104659-22-067763 · tm2217576d5_4seq1.xml · nonDerivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 218,633 F2 · ownership.nature: These shares are held by a family trust for which the reporting person is a trustee. Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 00:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 10,000 | $6.84 | $68,400.00 |
DisclosureSEC source: 0001104659-22-067763 · tm2217576d5_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,150 F1 · balance_after: An aggregate of 200,000 shares previously held by the reporting person were transferred as a bona fide gift earlier in 2022. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 19:41 UTC | Research Solutions, Inc. RSSS · Entity 6984 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-22-019586 · tm226259-1_4seq1.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-07 Read SEC document |
| November 05, 2021 Filed Aug 10, 2022 20:34 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionWarrant to purchase common stock · Derivative | 50,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001104659-22-088882 · tm2223165-1_4seq1.xml · derivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2021 Filed Aug 10, 2022 20:34 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionCommon Stock | 50,000 | $1.19 | $59,500.00 |
DisclosureSEC source: 0001104659-22-088882 · tm2223165-1_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 20:19 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $26.33 | $0.00 |
DisclosureSEC source: 0001104659-21-088252 · tm2121236-4_4seq1.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-06-29 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 29, 2022. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 19:39 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionCommon Stock Warrants (right to buy) · Derivative | 7,500 | $1.00 Strike: $1.25 | $7,500.00 |
DisclosureSEC source: 0001104659-21-079631 · tm2119436-3_4seq1.xml · derivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2021-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities were included within units purchased by the reporting person for $1.00 per unit. Each unit consisted of one share of common stock and one warrant to purchase three-tenths of one share of common stock Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 19:39 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionCommon Stock | 7,500 | $1.25 | $9,375.00 |
DisclosureSEC source: 0001104659-21-079631 · tm2119436-3_4seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2021 Filed Jan 20, 2022 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GiftCommon Stock | 37,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-005600 · tm223806-5_5seq1.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,783 F1 · price: Shares transferred as a bona fide gift without any consideration. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 20:52 UTC | Research Solutions, Inc. RSSS · Entity 6984 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001104659-20-127002 · tm2036363d1_4.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-11-16 Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 16:05 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionWarrant to purchase common stock · Derivative | 50,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001104659-20-114501 · tm2033115d1_4.xml · derivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2020-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 12,500 warrant shares vested and become exercisable on each of 12/31/10, 3/31/11, 6/30/11 and 9/30/11. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 16:05 UTC | Research Solutions, Inc. RSSS · Entity 6984 | Exercise / conversionCommon Stock | 50,000 | $1.25 | $62,500.00 |
DisclosureSEC source: 0001104659-20-114501 · tm2033115d1_4.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2020 Filed Jun 11, 2020 00:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $32.17 | $0.00 |
DisclosureSEC source: 0001104659-20-072140 · tm2022303d4_4.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 8, 2021. Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 21:18 UTC | Research Solutions, Inc. RSSS · Entity 6984 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001104659-19-064456 · tm1923024-5_4.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-11-11 Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 21:16 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $19.93 | $0.00 |
DisclosureSEC source: 0001144204-19-030594 · tv523379_4.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-06-09 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service, unless the Reporting Person is terminated for cause, in which case the options shall terminate immediately. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 17:30 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 217 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006942 · form4.xml · nonDerivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 63,912 F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. F3 · shares: Pursuant to the Director Compensation Program, if a Director elects to receive common stock in lieu of at least 50% of his cash compensation, the Company will grant restricted shares equal in value to 50% of the amount of cash compensation he elects to receive in common stock. Such restricted shares will vest on the earlier of (i) the date of the Director's retirement from the Board, and (ii) one year after the grant date. The number of shares of common stock shown reflects the grant of restricted shares. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 17:30 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006942 · form4.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 63,695 F1 · shares: Effective March 24, 2010, the Board of Directors approved a Director Compensation Program which allows Directors to elect to receive Aerojet Rocketdyne Holdings, Inc. common stock in lieu of their cash compensation. The number of shares of common stock shown reflects the common stock this Reporting Person is entitled to receive in lieu of his annual cash retainer fee paid quarterly. F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 10,000 | $9.63 | $96,273.00 |
DisclosureSEC source: 0001144204-18-064687 · tv509162_4.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,583 Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 16:53 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 243 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-18-003102 · form407319048mcp_11192018.xml · nonDerivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 63,260 F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. F3 · shares: Pursuant to the Director Compensation Program, if a Director elects to receive common stock in lieu of at least 50% of his cash compensation, the Company will grant restricted shares equal in value to 50% of the amount of cash compensation he elects to receive in common stock. Such restricted shares will vest on the earlier of (i) the date of the Director's retirement from the Board, and (ii) one year after the grant date. The number of shares of common stock shown reflects the grant of restricted shares. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 16:53 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 486 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-18-003102 · form407319048mcp_11192018.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 63,017 F1 · shares: Effective March 24, 2010, the Board of Directors approved a Director Compensation Program which allows Directors to receive Aerojet Rocketdyne Holdings, Inc. common stock in lieu of their cash compensation. The number of shares of common stock shown reflects the common stock received by this Reporting Person in lieu of his annual cash retainer fee paid quarterly. F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 21:02 UTC | Research Solutions, Inc. RSSS · Entity 6984 | GrantOption to purchase common stock · Derivative | 50,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001144204-18-060358 · tv507468_4.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-11-12 Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 17:36 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 241 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-025715 · form4.xml · nonDerivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 62,531 F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. F3 · shares: Pursuant to the Director Compensation Program, if a Director elects to receive common stock in lieu of at least 50% of his cash compensation, the Company will grant restricted shares equal in value to 50% of the amount of cash compensation he elects to receive in common stock. Such restricted shares will vest on the earlier of (i) the date of the Director's retirement from the Board, and (ii) one year after the grant date. The number of shares of common stock shown reflects the grant of restricted shares. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 17:36 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 483 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-025715 · form4.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 62,290 F1 · shares: Effective March 24, 2010, the Board of Directors approved a Director Compensation Program which allows Directors to elect to receive Aerojet Rocketdyne Holdings, Inc. common stock in lieu of their cash compensation. The number of shares of common stock shown reflects the common stock this Reporting Person is entitled to receive in lieu of his annual cash retainer fee paid quarterly. F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $14.45 | $0.00 |
DisclosureSEC source: 0001250853-18-000102 · primary_doc.xml · derivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-07-16 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service, unless the Reporting Person is terminated for cause, in which case the options shall terminate immediately. Read SEC document |
| May 15, 2018 Filed May 17, 2018 17:39 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 3,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017947 · form4.xml · nonDerivative · entry 3 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 61,807 F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. F4 · shares: Grant to Reporting Person of restricted stock under the Aerojet Rocketdyne Holdings, Inc. 2018 Equity and Performance Incentive Plan. Such shares of restricted stock will vest in 50% increments on November 15, 2018 and May 15, 2019. Read SEC document |
| May 15, 2018 Filed May 17, 2018 17:39 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 762 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017947 · form4.xml · nonDerivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 58,219 F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. F3 · shares: Pursuant to the Director Compensation Program, if a Director elects to receive common stock in lieu of at least 50% of his cash compensation, the Company will grant restricted shares equal in value to 50% of the amount of cash compensation he elects to receive in common stock. Such restricted shares will vest on the earlier of (i) the date of the Director's retirement from the Board, and (ii) one year after the grant date. The number of shares of common stock shown reflects the grant of restricted shares. Read SEC document |
| May 15, 2018 Filed May 17, 2018 17:39 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 1,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017947 · form4.xml · nonDerivative · entry 1 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 57,457 F1 · shares: Effective March 24, 2010, the Board of Directors approved a Director Compensation Program which allows Directors to elect to receive Aerojet Rocketdyne Holdings, Inc. common stock in lieu of their cash compensation. The number of shares of common stock shown reflects the common stock this Reporting Person is entitled to receive in lieu of his annual cash retainer fee paid quarterly. F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 12:21 UTC | AEROJET ROCKETDYNE HOLDINGS, INC. AJRD · Entity 111042 | GrantCommon Stock | 317 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006960 · form4.xml · nonDerivative · entry 2 MCPEAK MERRILL A · CIK 0001210317 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Rabbi Trust Disclosed balance after: 55,933 F2 · shares: Shares of common stock held by a "rabbi trust" receipt of which has been deferred by the Reporting Person pursuant to the Aerojet Rocketdyne Holdings, Inc. Deferred Compensation Plan for Directors. F3 · shares: Pursuant to the Director Compensation Program, if a Director elects to receive common stock in lieu of at least 50% of his cash compensation, the Company will grant restricted shares equal in value to 50% of the amount of cash compensation he elects to receive in common stock. Such restricted shares will vest on the earlier of (i) the date of the Director's retirement from the Board, and (ii) one year after the grant date. The number of shares of common stock shown reflects the grant of restricted shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.